Curbside Consult Volume 15, Issue 4 - Fourth Quarter 2017
Association of Genetic Variants with Lipoprotein Levels and Cardiovascular Risk
Joelle Ayoub, Pharm.D., Coborn’s Pharmacy-CHI St. Gabriel’s Health Family Medical Center
Do genetic variants affect changes in LDL, and therefore cardiovascular outcomes?
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI)
Thakul Rattanasuwan, PharmD, CentraCare Health-Paynesville
Dual therapy (dabigatran plus P2Y12 inhibitor) reduced the risk of major and clinically relevant nonmajor bleeds in patients with atrial fibrillation after PCI. Could it be an alternative to warfarin-based triple therapy?
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Courtney Murphy, Pharm.D., Essentia Health
Aspirin therapy is currently used for secondary prevention of cardiovascular events, but each year 5-10% of patients with cardiovascular disease still have a recurrent event. This randomized controlled trial investigates rivaroxaban as another potential secondary prevention strategy.
Medication Overuse Headaches
Natalie Roy, PharmD, MHealth Neurology Clinic
Should medication overuse in the treatment of headaches be regarded as a cause or a consequence?
Smoking Cessation and Secondary Stroke Prevention
Dana Osdoba, PharmD, Hennepin County Medical Center
The AHA/ASA guidelines recommend smoking cessation to reduce the risk of secondary stroke, however, few studies have been conducted to show evidence proving this is beneficial. Although the IRIS study was not designed to provide evidence of this either, a secondary analysis of the data shows hypothesis-generating results.
Is Biotin Baffling Your Lab Results?
Morgan Stoa, PharmD, Community University Health Care Center
Mega-doses of the common supplement biotin may be interfering with a number of common laboratory tests.
From the Pharmacy Press
Pharmacist Involvement in Opioid Stewardship and its Impact in a Small Community Health System
Barbara Truskolawski, PharmD, CashWise Pharmacy
Interdisciplinary interventions show significant changes in opioid use and concurrent benzodiazepine use at a small community health system.
Weighing in on Amazon’s Entry into the Pharmacy Industry
Eli Eggen, PharmD, West Side Community Health Services
“Alexa, refill my blood pressure medications.” Can Amazon disrupt the delivery of healthcare?
Continuous Blood Glucose Monitoring in a Flash
Dema Mohammed, PharmD, Community-University Health Care Center
The FDA has approved the first continuous glucose monitoring system which does not require a blood sample for calibration. The FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL-CGM) allows patients to make diabetes treatment decisions without the need for fingerstick, which may be burdensome and sometimes painful for patients.
Welcome to the Quadruple Aim
Logane Kiehnau, Pharm.D., Allina Health
Have you heard of the Quadruple Aim? Taking provider satisfaction into account and recognizing the financial ramifications of doing so is imperative.
The Promise of SGLT-2 Inhibition in Heart Failure
Elizabeth So, Pharm.D, MBA, Cub Pharmacy
SGLT-2 inhibitors may have a role in the treatment of heart failure primarily through their inhibition of sodium-hydrogen exchange in both the kidney and the heart.
New Drug Update
Shingrix® (zoster vaccine recombinant, adjuvanted), developed by GlaxoSmithKline
Kaity Kuske, Pharm.D., Smiley’s Family Medicine Clinic